Modernizing Medicare Part D: Proposed PBM Regulations and Their Impact
The Centers for Medicare & Medicaid Services (CMS) has unveiled a proposed rule to modernize Medicare Part D pharmacy benefit manager (PBM) operations, potentially reshaping prescription drug market norms.
Released on October 20, 2026, the CMS-proposed rule introduces transformative changes aimed at increasing transparency and oversight within the Medicare Part D space. These reforms are part of Section 6224 of the Consolidated Appropriations Act (CAA) of 2026. If implemented, the changes would introduce new standards for PBMs, such as cost-plus, fair market value for service fee arrangements, full pass-through of manufacturer rebates to plan sponsors, and enhanced federal scrutiny.
Understanding the Proposed Regulations
The proposed rule would redefine PBM industry operations by focusing on several key areas. Most significantly, from 2028, PBMs involved in managing prescription drug plans will face strict accountability. This includes new definitions based on functional roles rather than titles, ensuring all economic value from manufacturer concessions reaches Part D sponsors. The PBMs will also need to submit detailed annual revenue reports to both CMS and plan sponsors. These measures aim to improve financial transparency and reduce conflicts of interest that can arise from PBM-manufacturer interactions.
Implications for Insurance and Pharmaceutical Markets
If these rules are formalized, they could bring substantial changes to how pharmaceutical companies engage with Medicare Part D plans. The mandate for complete rebate pass-through signifies a shift that could influence market access agreements and pharmaceutical pricing strategies. Moreover, increased federal oversight and stricter reporting requirements could alter the landscape of PBM negotiations and partnerships.
| Proposed Action | Details |
|---|---|
| PBM and Affiliate Definition | Define based on roles and functions, not labels. |
| Compensation Restrictions | Flat bona fide service fees only. |
| Rebate Pass-Through Requirement | Sponsors receive all manufacturer rebates. |
| Transparency Measures | Annual revenue reports from July 2028. |
Focus on Compliance and Transparency
The emphasis on compliance and transparency underscores a broader regulatory effort to mitigate market complexities and promote equitable financial practices. CMS will collaborate with the HHS Office of Inspector General to scrutinize PBM and manufacturer agreements more closely. Additionally, there will be mechanisms to address violations, ensuring accountability and rectification of noncompliance.
While these proposed rules do not immediately address commercial market regulations under Section 6702, they highlight significant implications for future regulatory approaches. Industry stakeholders have until December 15, 2026, to provide feedback on these proposals. The impending changes underscore the necessity for continuous engagement and strategic adaptation within the ever-evolving insurance landscape.